PDS Biotechnology to Showcase Innovations at Virtual Event
PDS Biotechnology Corporation (Nasdaq: PDSB), a pioneering force in immunotherapy dedicated to revolutionizing cancer treatment, has exciting news to share. Frank Bedu-Addo, PhD, the President and CEO of PDS Biotech, is set to participate in a fireside chat at the upcoming Alliance Global Partners (A.G.P.) Virtual Annual Healthcare Company Showcase. This event promises to be a platform for insightful discussions and innovations happening in the healthcare sector.
Understanding the Event Details
The A.G.P. Virtual Annual Healthcare Company Showcase is scheduled for May 21, and it will feature an array of industry leaders and innovators sharing their expertise and advancements in medical science. Frank Bedu-Addo's participation is highly anticipated, as it will offer valuable insights into the advancements at PDS Biotech and their ongoing efforts to enhance immunotherapy solutions.
Event Specifics
The details surrounding the fireside chat are as follows:
- Date: May 21
- Time: 5:20–5:40 p.m. ET
- Format: Virtual fireside chat
This presentation is not just a chance to hear about PDS Biotech's innovative approaches but also an opportunity for industry professionals and investors to engage and ask questions. Those interested in participating can reach out to their A.G.P. representatives for one-on-one meetings with the PDS Biotech leadership team.
PDS Biotech’s Commitment to Cancer Treatment
PDS Biotechnology Corporation is at the forefront of immunotherapy, focusing on developing treatments that harness the body's immune system to combat cancer cells. Their lead investigational treatment, Versamune® HPV, is currently undergoing pivotal trials aimed at addressing advanced HPV16-positive head and neck squamous cell cancers.
Innovative Research and Development Initiatives
The company is not only working on Versamune® HPV; they are also exploring its effectiveness in combination with standard-of-care treatments, including immune checkpoint inhibitors. This combination therapy is designed to enhance patient outcomes and provide a more comprehensive approach to cancer care. Furthermore, they are researching a triple therapy that would incorporate PDS01ADC, an IL-12 fused antibody-drug conjugate, with their existing regimens.
Exploring Future Communications
For those eager to learn more about PDS Biotech and their innovative research initiatives, the company’s website will host an archived replay and transcript of the fireside chat shortly after the event. Engaging with the content available there will provide deeper insights into their endeavors and future direction.
About PDS Biotechnology Corporation
PDS Biotechnology is dedicated to advancing immunotherapy solutions that promise to shift paradigms in cancer treatment. Their commitment to research and innovation is evident in their robust clinical trial program, which seeks to develop therapies that effectively target and eliminate cancer cells.
Contacting PDS Biotech
Those looking to connect with PDS Biotech can reach out to:
Investor Contact:
Mike Moyer
LifeSci Advisors
Phone: +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Contact:
Janine McCargo
6 Degrees
Phone: +1 (646) 528-4034
Email: jmccargo@6degreespr.com
Frequently Asked Questions
What is PDS Biotech focusing on during the showcase?
PDS Biotech will highlight their innovations in immunotherapy and the advancements in their clinical trial programs.
Who is participating in the fireside chat?
Frank Bedu-Addo, PhD, the President and CEO of PDS Biotech, will lead the discussion.
What therapies is PDS Biotech developing?
PDS Biotech is developing several therapies, including Versamune® HPV combined with immune checkpoint inhibitors and PDS01ADC.
How can investors engage with PDS Biotech?
Investors can schedule one-on-one meetings through A.G.P. representatives for in-depth discussions.
Where can I find more information about the company?
Visit www.pdsbiotech.com for more details and updates on PDS Biotech's developments.
